Skip to Content
Merck
  • Novel nanoparticulate gel formulations of steroids for the treatment of macular edema.

Novel nanoparticulate gel formulations of steroids for the treatment of macular edema.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics (2010-02-13)
Sai H S Boddu, Jwala Jwala, Ravi Vaishya, Ravinder Earla, Pradeep K Karla, Dhananjay Pal, Ashim K Mitra
ABSTRACT

This article describes the development and characterization of PLGA nanoparticles of dexamethasone (DEX), hydrocortisone acetate (HA), and prednisolone acetate (PA) suspended in thermosensitive gels indicated for the treatment of macular edema (ME). Nanoparticles were prepared by oil-in-water (O/W) emulsion and dialysis methods using PLGA 50:50 and PLGA 65:35. These particles were characterized for entrapment efficiency, size distribution, surface morphology, crystallinity, and in vitro release. Further, ex vivo permeation studies of DEX in suspension and nanoparticulate formulations were carried out across the rabbit sclera. Entrapment efficiencies of DEX, HA, and PA were found to be lower with the dialysis method. O/W emulsion/solvent evaporation technique resulted in higher entrapment efficiencies, that is, 77.3%, 91.3%, 92.3% for DEX, HA, and PA, respectively. Release from nanoparticles suspended in thermosensitive gels followed zero-order kinetics with no apparent burst effect. Ex vivo permeability studies further confirmed sustained release of DEX from nanoparticles suspended in thermosensitive gels. These novel nanoparticulate systems containing particles suspended in thermosensitive gels may provide sustained retina/choroid delivery of steroids following episcleral administration.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Hydrocortisone 21-acetate, meets USP testing specifications
Sigma-Aldrich
Hydrocortisone 21-acetate, ≥98% (HPLC)
Hydrocortisone acetate, European Pharmacopoeia (EP) Reference Standard